Imaging of HER-2 overexpression in tumors for guiding therapy

Current Pharmaceutical Design

Volumn 14, Issue 28, 2008, Pages 2999-3019

  Tolmachev, Vladimir ^a,b,c  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c Affibody AB   (Sweden)

Author keywords

Affibody molecule; Antibody fragment; HER2; Monoclonal antibody; Radionuclide imaging; Tumor targeting

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; BROMINE 76; CARBON 11; COBALT; COPPER; COPPER 64; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORINE 18; GALLIUM 68; INDIUM 111; IODINE 123; IODINE 124; ISOTHIOCYANIC ACID DERIVATIVE; NITROGEN 13; OXYGEN 15; PENTETATE INDIUM IN 111; PENTETIC ACID DERIVATIVE; RADIOISOTOPE; TECHNETIUM 99M; TOSYLCHLORAMIDE SODIUM; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; YTTRIUM 86; ZIRCONIUM; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; HYBRID PROTEIN; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT;

BLADDER CANCER; BREAST CANCER; CANCER CELL CULTURE; CANCER SURVIVAL; DRUG TARGETING; FOLLOW UP; GENE OVEREXPRESSION; GENETIC ENGINEERING; HEART DISEASE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR IMAGING; NONHUMAN; OVARY CANCER; PATIENT CARE; PATIENT MONITORING; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SAMPLING ERROR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; ANIMAL; DRUG DELIVERY SYSTEM; GENE EXPRESSION REGULATION; METABOLISM; NEOPLASM; SCINTISCANNING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS;

EID: 58149095508     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786404290     Document Type: Review

References (186)

1. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol 2006; 2: 689-700.
2. Nunn AD. Update: Molecular imaging and Aersonalized medicine: an uncertain future. Cancer Biother Radiopharm 2007; 22: 722-39.
3. Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-54.
4. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37.
5. Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 2004; 58: 903-13.
6. Citri A, Yarden Y. EGF-ERBB signalling: Towards the systems level. Nat Rev Mol Cell Biol 2006; 7: 505-16.
7. Bublil EM, Yarden Y. The EGF receptor family: Spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 2007; 19: 124-34.
8. Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 1999; 96: 4995-5000.
9. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996; 16: 5276-87.
10. Masood S, Bui MM. Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: An immunohistochemical study. Ann Clin Lab Sci 2000; 30: 259-65.
11. Simon R, Nocito A, Hubscher T, Bucher C, Torhorst J, Schraml P, et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001; 93: 1141-6.
12. Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002; 13: 1036-43
13. Carlsson J, Nordgren H, Sjostrom J, Wester K, Villman K, Bengtsson NO, et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 2004; 90: 2344-8
14. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005; 93: 552-6
15. Wester K, Sjostrom A, de la Torre M, Carlsson J, Malmstrom PU. HER-2-a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol 2002; 41: 282-8.
16. Latif Z, Watters AD, Dunn I, Grigor K, Underwood MA, Bartlett JM. HER2/ neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: A role for anti-HER2 therapy? Eur J Cancer 2004; 40: 56-63.
17. Rotterud R, Nesland JM, Berner A, Fossa SD. Expression of the epidermal growth factor receptor family in normal and malignant urothelium. BJU Int 2005; 95: 1344-50.
18. Gårdmark T, Wester K, De la Torre M, Carlsson J, Malmström PU. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int 2005; 95: 982-6.
19. Knosel T, Petersen S, Schwabe H, Schluns K, Stein U, Schlag PM, et al. Incidence of chromosomal imbalances in advanced colorectal carcinomas and their metastases. Virchows Arch 2002; 440: 187-94.
20. Hernes E, Fossa SD, Berner A, Otnes B, Nesland JM. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer 2004; 90: 449-54.
21. Bartlett JM, Brawley D, Grigor K, Munro AF, Dunne B, Edwards J. Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer. J Pathol 2005; 205: 522-9
22. Verri E, Guglielmini P, Puntoni M, Perdelli L, Papadia A, Lorenzi P, et al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: Evaluation of its prevalence and prognostic significance. Clinical study. Oncology 2005; 68: 154-61.
23. Wei Q, Sheng L, Shui Y, Hu Q, Nordgren H, Carlsson J. EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. Ann Surg Oncol 2008; [Epub ahead of print].
24. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. The Her-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy. Oncologist 2003; 8: 307-25.
25. Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: From the Danish MALOVA ovarian cancer study. Cancer 2003; 98: 66-73.
26. Kolla SB, Seth A, Singh MK, Gupta NP, Hemal AK, Dogra PN, et al. Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int Urol Nephrol 2007; [Epub ahead of print].
27. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: A metaanalysis. Cancer 2005; 103: 1865-73.
28. Cavalot A, Martone T, Roggero N, Brondino G, Pagano M, Cortesina G. Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck 2007; 29: 655-64.
29. Morote J, de Torres I, Caceres C, Vallejo C, Schwartz S Jr, Reventos J. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer. Int J Cancer 1999; 84: 421-5.
30. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344(11): 783-92.
31. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
32. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72.
33. Attard G, Kitzen J, Blagden SP, Fong PC, Pronk LC, Zhi J, et al. A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br J Cancer 2007; 97: 1338-43.
34. Herbst RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, et al. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res 2007; 13: 6175-81.
35. Spector N, Xia W, El-Hariry I, Yarden Y, Bacus S. HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors. Breast Cancer Res 2007; 9: 205.
36. Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, et al. A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res 2004; 64: 6200-6.
37. Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, et al. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res 2004; 10: 7834-41.
38. 212Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm 2005; 20: 557-68.
39. 177Lu]pertuzumab: Experimental therapy of HER-2-expressing xenografts. Cancer Res 2007; 67: 326-31.
40. 177Lu-labeled HER2-specific Affibody molecule. Cancer Res 2007; 67: 2773-82.
41. 111In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): An Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med 2007; 48: 1357-68.
42. Mandler R, Wu C, Sausville EA, Roettinger AJ, Newman DJ, Ho DK, et al. Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: Antiproliferative activity on human breast carcinoma cell lines. J Natl Cancer Inst 2000; 92: 1573-81.
43. Citri A, Kochupurakkal BS, Yarden Y. The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 2004; 3: 51-60.
44. Solit DB, Chiosis G. Development and application of Hsp90 inhibitors. Drug Discov Today 2008; 13: 38-43.
45. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1865-78
46. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumour Biol 2005; 26: 281-93.
47. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260-6.
48. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90: 1361-70.
49. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996; 14: 2702-8.
50. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderborgh J, Anbazhagan R, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992; 10: 1049-56.
51. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, et al. Real-world performance of HER2 testing-National surgical adjuvant breast and bowel project experience. J Natl Cancer Inst 2002; 94: 852-4.
52. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006; 24: 3032-8.
53. Becker S, Becker-Pergola G, Fehm T, Wallwiener D, Solomayer EF. Her2 expression on disseminated tumor cells from bone marrow of breast cancer patients. Anticancer Res 2005; 25: 2171-5.
54. Weissleder R. Molecular imaging in cancer. Science 2006; 312: 1168-71
55. Choy G, Choyke P, Libutti SK. Current advances in molecular imaging: noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research. Mol Imaging 2003; 2: 303-12.
56. Hoffman RM. Advantages of multi-color fluorescent proteins for whole-body and in vivo cellular imaging. J Biomed Opt 2005; 10: 41202.
57. Cai W, Niu G, Chen X. Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging 2008; 35: 186-208.
58. 99mTc radiopharmaceuticals. Ann Nucl Med 2002; 16: 79-93.
59. Jurisson SS, Lydon JD. Potential technetium small molecule radio-pharmaceuticals. Chem Rev 1999; 99: 2205-18.
60. Knapp FF Jr, Mirzadeh S. The continuing important role of radionuclide generator systems for nuclear medicine. Eur J Nucl Med 1994; 21: 1151-65.
61. Lundqvist H, Lubberink M, Tolmachev V. Positron emission tomography. Eur J Physics 1998; 19: 537-552.
62. Wester HJ, Schottelius M, Poethko T, Bruus-Jensen K, Schwaiger M. Radiolabeled carbohydrated somatostatin analogs: A review of the current status. Cancer Biother Radiopharm 2004; 19: 231-44.
63. Lundqvist H, Lubberink M, Tolmachev V, Lövqvist A, Sundin A, Beshara S, et al. Positron emission tomography and radioimmuno-targeting. General aspects. Acta Oncologica 1999; 38: 335-41.
64. Verel I, Visser GW, van Dongen GA. The promise of immuno-PET in radioimmunotherapy. J Nucl Med 2005; 46: 164S-71S.
65. van Dongen GA, Visser GW, Lub-de Hooge MN, de Vries EG, Perk LR. Immuno-PET: A navigator in monoclonal antibody development and applications. Oncologist 2007; 12: 1379-89.
66. Lundqvist H, Tolmachev V. Targeting peptides and positron emission tomography. Biopolymers 2002; 66: 381-92.
67. 18F-radiopharmacy. Ernst Schering Res Found Workshop 2007: 215-42.
68. 68Ga bioconjugates with high specific radioactivity. Bioconjug Chem 2004; 15: 554-60.
69. 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007; 34: 1617-26
70. 3-octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48: 508-18.
71. 18FFDG. J Nucl Med 2007; 48: 1245-50.
72. Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000; 7: 971-94.
73. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003; 24: 389-427.
74. Eberle AN, Mild G, Froidevaux S. Receptor-mediated tumor targeting with radiopeptides. Part 1. General concepts and methods: Applications to somatostatin receptor-expressing tumors. J Recept Signal Transduct Res 2004; 24: 319-455.
75. Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP. Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 2007; 21: 111-29.
76. Dijkgraaf I, Boerman OC, Oyen WJ, Corstens FH, Gotthardt M. Development and application of peptide-based radiopharmaceuticals. Anticancer Agents Med Chem 2007; 7: 543-51.
77. Senekowitsch-Schmidtke R, Steiner K, Haunschild J, Mollenstadt S, Truckenbrodt R. In vivo evaluation of epidermal growth factor (EGF) receptor density on human tumor xenografts using radiolabeled EGF and anti-(EGF receptor) mAb 425. Cancer Immunol Immunother 1996; 42(2): 108-14.
78. Hnatowich DJ, Qu T, Chang F, Ley AC, Ladner RC, Rusckowski M. Labeling peptides with technetium-99m using a bifunctional chelator of a N-hydroxysuccinimide ester of mercaptoacetyltriglycine. J Nucl Med 1998; 39: 56-64.
79. 99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: Preparation and pre-clinical evaluation. Oncol Rep 2005; 13: 1169-75.
80. 68Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med 2005; 46: 1881-8.
81. Reilly RM. The Radiopharmaceutical Science of Monoclonal Antibodies and Peptides for Imaging and Targeted in situ Radiotherapy of Malignancies. In: Gad S, Ed. Handbook of Pharmaceutical Biotechnology. John Wiley and Sons, Inc., Hoboken, NJ 2007; 883-942.
82. Crumpton MJ, Owens RJ, Gallagher CJ, Davies AA. The cell surface and its metabolism. J Pathol 1983; 141: 235-48.
83. Wiley HS. Trafficking of the ErbB receptors and its influence on signaling. Exp Cell Res 2003; 284: 78-88.
84. Kyriakos RJ, Shih LB, Ong GL, Patel K, Goldenberg DM, Mattes MJ. The fate of antibodies bound to the surface of tumor cells in vitro. Cancer Res 1992; 52: 835-42.
85. Tolmachev V, Orlova A, Lundqvist H. Approaches to improve cellular retention of radiohalogen labels delivered by internalising tumour-targeting proteins and peptides. Curr Med Chem 2003; 10: 2447-60.
86. 125I-glycoconjugate labels for identifying sites of protein catabolism in vivo: Effect of structure and chemistry of coupling to protein on label entrapment in cells after protein degradation. Arch Biochem Biophys 1985; 240: 635-45.
87. Brechbiel MW. Bifunctional chelates for metal nuclides. Q J Nucl Med Mol Imaging 2008; 52: 166-73.
88. Lundberg E, Höidén-Guthenberg I, Larsson B, Uhlén M, Gräslund T. Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. J Immunol Methods 2007; 319: 53-63.
89. Saga T, Endo K, Akiyama T, Sakahara H, Koizumi M, Watanabe Y, et al. Scintigraphic detection of overexpressed c-erbB-2 protooncogene products by a class-switched murine anti-c-erbB-2 protein monoclonal antibody. Cancer Res 1991; 51: 990-4.
90. De Santes K, Slamon D, Anderson SK, Shepard M, Fendly B, Maneval D, et al. Radiolabeled antibody targeting of the HER-2/neu oncoprotein Cancer Res 1992; 52: 1916-23.
91. Bakir MA, Eccles S, Babich JW, Aftab N, Styles J, Dean CJ, et al. c-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies. J Nucl Med 1992; 33: 2154-60.
92. Xu FJ, Yu YH, Bae DS, Zhao XG, Slade SK, Boyer CM, et al. Radioiodinated antibody targeting of the HER-2/neu oncoprotein. Nucl Med Biol 1997; 24: 451-9.
93. Smellie WJ, Dean CJ, Sacks NP, Zalutsky MR, Garg PK, Carnochan P, et al. Radioimmunotherapy of breast cancer xenografts with monoclonal antibody ICR12 against c-erbB2 p185: Comparison of iodogen and N-succinimidyl 4-methyl-3-(tri-n-butylstannyl) benzoate radioiodination methods. Cancer Res 1995; 55: 5842s-5846s.
94. Zalutsky MR, Xu FJ, Yu Y, Foulon CF, Zhao XG, Slade SK, et al. Radioiodinated antibody targeting of the HER-2/neu oncoprotein: Effects of labeling method on cellular processing and tissue distribution. Nucl Med Biol 1999; 26: 781-90.
95. Mume E, Orlova A, Malmström PU, Lundqvist H, Sjöberg S, Tolmachev V. Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridine-carboxylate, a potential label for immunoPET. Nucl Med Biol 2005; 32: 613-22.
96. 125I]-(4-isothiocyanatobenzylammonio)-iodo-decahydro-closo -dodecaborate (iodo-DABI). Anticancer Res 2006; 26: 1217-23.
97. 76Br] (4 isothiocyanatobenzyl-ammonio)-bromo-decahydro-closododecaborate (Bromo-DABI). Nucl Med Biol 2004; 31: 205-11.
98. 76Brundeca-hydro-bromo-7,8-dicarba-nido-undecaborate(1-) ion. Nucl Med Biol 2004; 31: 425-33.
99. Persson M, Sivaev I, Winberg KJ, Gedda L, Malmström PU, Tolmachev V. In vitro evaluation of two polyhedral boron anion derivatives as linkers for attachment of radioiodine to the anti-HER2 monoclonal antibody trastuzumab. Cancer Biother Radiopharm 2007; 22: 585-96.
100. Tsai SW, Sun Y, Williams LE, Raubitschek AA, Wu AM, Shively JE. Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5. Bioconjug Chem 2000; 11: 327-34
101. 90Y using a bifunctional DTPA chelating agent. Cancer Biother Radiopharm 2003; 18: 355-63.
102. 111In labeled Herceptin. Nucl Med Biol 2002; 29: 599-606.
103. 90Y dosimetry in an ovarian carcinoma model: Correlative MicroPET and MRI. J Nucl Med 2003; 44: 1148-55.
104. 111In-DTPA-trastuzumab. Br J Pharmacol 2004; 143: 99-106.
105. Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006; 24: 2276-82.
106. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 2007; 43: 2046-51.
107. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 2000; 65: 271-84.
108. Wu AM, Senter PD. Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol 2005; 23: 1137-46.
109. Kenanova V, Wu AM. Tailoring antibodies for radionuclide delivery. Expert Opin Drug Deliv 2006; 3: 53-70.
110. Smith-Jones PM, Solit DB. Generation of DOTA-conjugated antibody fragments for radioimmunoimaging. Methods Enzymol 2004; 386: 262-75
111. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004; 22: 701-6.
112. 18F-FDG PET. J Nucl Med 2006; 47: 793-6.
113. Tang Y, Wang J, Scollard DA, Mondal H, Holloway C, Kahn HJ, et al. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragments. Nucl Med Biol 2005; 32: 51-8.
114. 99mTc]-HYNIC-trastuzumab (Herceptin) Fab fragments. Nucl Med Commun 2005; 26: 427-32.
115. Wu AM, Yazaki PJ. Designer genes: Recombinant antibody fragments for biological imaging. Q J Nucl Med 2000; 44: 268-83.
116. Adams GP, McCartney JE, Tai MS, Oppermann H, Huston JS, Stafford WF 3rd, et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 1993; 53: 4026-34.
117. Adams GP, McCartney JE, Wolf EJ, Eisenberg J, Huston JS, Bookman MA, et al. Enhanced tumor specificity of 741F8-1 (sFv')2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugation. J Nucl Med 1995; 36: 2276-81.
118. Huston JS, Adams GP, McCartney JE, Tai MS, Hudziak RM, Oppermann H, et al. Tumor targeting in a murine tumor xenograft model with the (sFv')2 divalent form of anti-c-erbB-2 single-chain Fv. Cell Biophys 1994; 24-25: 267-78.
119. Tai MS, McCartney JE, Adams GP, Jin D, Hudziak RM, Oppermann H, et al. Targeting c-erbB-2 expressing tumors using singlechain Fv monomers and dimers. Cancer Res 1995; 55 (23 Suppl): 5983s-5989s.
120. Adams GP, McCartney JE, Wolf EJ, Eisenberg J, Tai MS, Huston JS, et al. Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: Effects of dose escalation and repeated i.v. administration. Cancer Immunol Immunother 1995; 40: 299-306.
121. Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, et al. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 1998; 58: 485-90.
122. Adams GP, Tai MS, McCartney JE, Marks JD, Stafford WF 3rd, Houston LL, et al. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res 2006; 12: 1599-605.
123. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001; 61: 4750-5
124. Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 1998; 77: 1405-12.
125. Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tasfaye A, et al. A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res 2004; 64: 6200-6.
126. 124I activity distributions using a clinical PET/CT scanner. J Nucl Med 2004; 45: 1237-44.
127. Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 2005; 65: 1471-8.
128. Hu S, Shively L, Raubitschek A, Sherman M, Williams LE, Wong JY, et al. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996; 56: 3055-61.
129. Olafsen T, Tan GJ, Cheung CW, Yazaki PJ, Park JM, Shively JE, et al. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel 2004; 17: 315-23.
130. Olafsen T, Kenanova VE, Sundaresan G, Anderson AL, Crow D, Yazaki PJ, et al. Optimizing radiolabeled engineered anti-p185-HER2 antibody fragments for in vivo imaging. Cancer Res 2005; 65: 5907-16.
131. Nguyen A, Reyes AE 2nd, Zhang M, McDonald P, Wong WL, Damico LA, et al. The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng Des Sel 2006; 19: 291-7.
132. Dennis MS, Jin H, Dugger D, Yang R, McFarland L, Ogasawara A, et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res 2007; 67: 254-61
133. Revets H, De Baetselier P, Muyldermans S. Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther 2005; 5: 111-24.
134. Levin AM, Weiss GA. Optimizing the affinity and specificity of proteins with molecular display. Mol Biosyst 2006; 2: 49-57.
135. Rothe A, Hosse RJ, Power BE. In vitro display technologies reveal novel biopharmaceutics. FASEB J 2006; 20: 1599-610.
136. Hosse RJ, Rothe A, Power BE. A new generation of protein display scaffolds for molecular recognition. Protein Sci 2006; 15: 14-27.
137. Karasseva NG, Glinsky VV, Chen NX, Komatireddy R, Quinn TP. Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library. J Protein Chem 2002; 21: 287-96.
138. 111Inradiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor expressing breast carcinomas. Clin Cancer Res 2007; 13: 6070-9.
139. Shrivastava A, von Wronski MA, Sato AK, Dransfield DT, Sexton D, Bogdan N, et al. A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases. Protein Eng Des Sel 2005; 18(9): 417-24.
140. Kennel SJ, Mirzadeh S, Hurst GB, Foote LJ, Lankford TK, Glowienka KA, et al. Labeling and distribution of linear peptides identified using in vivo phage display selection for tumors. Nucl Med Biol 2000; 27: 815-25.
141. Froidevaux S, Eberle AN, Christe M, Sumanovski L, Heppeler A, Schmitt JS, et al. Neuroendocrine tumor targeting: Study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model. Int J Cancer 2002; 98: 930-7.
142. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007; 34: 982-93.
143. Nygren PA, Uhlén M .Scaffolds for engineering novel binding sites in proteins. Curr Opin Struct Biol 1997; 7: 463-9.
144. Binz HK, Amstutz P, Pluckthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 2005; 23: 1257-68.
145. Hey T, Fiedler E, Rudolph R, Fiedler M. Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. Trends Biotechnol 2005; 23: 514-22.
146. Skerra A. Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol 2007; 18: 295-304.
147. Stumpp MT, Amstutz P. DARPins: A true alternative to antibodies. Curr Opin Drug Discov Devel 2007; 10: 153-9.
148. Zahnd C, Pecorari F, Straumann N, Wyler E, Plückthun A. Selection and characterization of Her2 binding-designed ankyrin repeat proteins. J Biol Chem 2006; 281: 35167-75.
149. Zahnd C, Wyler E, Schwenk JM, Steiner D, Lawrence MC, McKern NM, et al. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J Mol Biol 2007; 369: 1015-28.
150. Nygren PA. Alternative binding proteins: Affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J 2008; 275: 2668-76.
151. Nord K, Gunneriusson E, Ringdahl J, Stähl S, Uhlén M, Nygren PÅ. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol 1997; 15: 772-7.
152. Nord K, Gunneriusson E, Uhlén M, Nygren PÅ, Ligands selected from combinatorial libraries of protein A for use in affinity capture of apolipoprotein A-1M and taq DNA polymerase. J Biotechnol 2000; 80: 45-54.
153. Rönnmark J, Kampf C, Asplund A, Höiden-Guthenberg I, Wester K, Ponten F, et al. Affibody-beta-galactosidase immunoconjugates produced as soluble fusion proteins in the Escherichia coli cytosol. J Immunol Methods 2003; 281: 149-60.
154. Renberg B, Shiroyama I, Engfeldt T, Nygren PK, Eriksson Karlstöm A. Affibody protein capture microarrays: Synthesis and evaluation of random and directed immobilization of affibody molecules. Anal Biochem 2005; 341: 334-43.
155. Tolmachev V, Orlova A, Nilsson FY, Feldwisch J, Wennborg A, Abrahmsén L. Affibody molecules: Potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin Biol Ther 2007; 7: 555-68.
156. Wikman M, Steffen AC, Gunneriusson E, Tolmachev V, Adams GP, Carlsson J, et al. Selection and characterisation of HER2/neubinding affibody ligands. Protein Eng Des Sel 2004; 17: 455-62.
157. Nilsson FY, Tolmachev V. Affibody molecules: New protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Devel 2007; 10: 167-75.
158. Orlova A, Feldwisch J, Abrahmsen L, Tolmachev V. Update: Affibody molecules for molecular imaging and therapy for cancer. Cancer Biother Radiopharm 2007; 22: 573-84.
159. Steffen AC, Wikman M, Tolmachev V, Adams GP, Nilsson FY, Ståhl S, et al. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics Cancer Biother Radiopharm 2005; 20: 239-48.
160. Steffen AC, Orlova A, Wikman M, Nilsson FY, Ståhl S, Adams GP, et al. Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. Eur J Nucl Med Mol Imaging 2006; 33(6): 631-8.
161. Orlova A, Nilsson FY, Wikman M, Widström C, Ståhl S, Carlsson J, et al. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. J Nucl Med 2006; 47: 512-9.
162. Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, Höidén-Guthenberg I, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 2006; 66: 4339-48.
163. 111In-benzyl-DTPA-ZHER2: 342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med 2006; 47: 846-53.
164. 342, a potential agent for imaging of HER2 expression in malignant tumors. Int J Mol Med 2007; 20: 397-404.
165. 111/114mIn]CHX-A"-DTPA-Z(HER2: 342), an Affibody ligand coniugate for targeting of HER2-expressing malignant tumors. Q J Nucl Med Mol Imaging 2007; 51: 314-23.
166. 342-pep2: Implications for development of labeled tracers Cancer Biother Radiopharm 2008; 23: 435-42.
167. Engfeldt T, Renberg B, Brumer H, Nygren PÅ, Eriksson Karlström A. Chemical synthesis of triple-labelled three-helix bundle binding proteins for specific fluorescent detection of unlabelled protein. Chembiochem 2005; 6: 1043-50.
168. Orlova A, Tolmachev V, Pehrson R, Lindborg M, Tran T, Sandström M, et al. Synthetic affibody molecules: A novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 2007; 67: 2178-86.
169. 99mTc-chelating mercaptoacetylglycyl-glycyl-glycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging 2007; 34: 722-33.
170. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. Eur J Nucl Med Mol Imaging 2007; 34: 1843-53.
171. 342, an Affibody moleculebased tracer for the detection of HER2 expression in malignant tumors. Bioconjug Chem 2007; 18: 1956-64.
172. Mume E, Orlova A, Larsson B, Nilsson AS, Nilsson FY, Sjöberg S, et al. Evaluation of ((4-hydroxyphenyl) ethyl)maleimide for sitespecific radiobromination of anti-HER2 affibody. Bioconjug Chem 2005; 16: 1547-55.
173. 342-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging 2008; 35: 1008-18.
174. Liberatore M, Neri D, Neri G, Pini A, Iurilli AP, Ponzo F, et al. Efficient one-step direct labelling of recombinant antibodies with technetium-99m. Eur J Nucl Med 1995; 22: 1326-9.
175. 99TcO] apcitide: A technetium labeled peptide. Inorg Chem 2004; 43: 2867-75.
176. George AJ, Jamar F, Tai MS, Heelan BT, Adams GP, McCartney JE, et al. Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: Technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide. Proc Natl Acad Sci USA 1995; 92: 8358-62.
177. 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. J Nucl Med 2006; 47: 1707-16.
178. 99mTc to tumor-targeting Affibody molecules. Bioconjug Chem 2007; 18: 549-58.
179. 342 with C-terminal engineered cysteine. Eur J Nucl Med Mol Imaging 2007; 34 (Suppl 2): S190.
180. Ahlgren S, Orlova A, Rosik D, Sandström M, Sjöberg A, Baastrup B, et al. Evaluation of Maleimide Derivative of DOTA for Site-Specific Labeling of Recombinant Affibody Molecules. Bioconjug Chem 2008; 19: 235-43.
181. Behr TM, Béhé M, Wörmann B. Trastuzumab and breast cancer. N Engl J Med 2001; 345: 995-6.
182. 89Zr-trastuzumab for clinical HER2 immunoPET imaging. J Clin Oncol (Meeting Abstracts) 2007; 25 (Suppl): 3508.
183. Baum RP, Orlova A, Tolmachev V, Feldwisch J. A novel molecular imaging agent for diagnosis of recurrent HER2 positive breast cancer. First time in human study using an Indium-111- or Gallium-68-labelled Affibody molecule. Eur J Nucl Med Mol Imaging 2006; 33; S91.
184. Adachi Y, Yoshio-Hoshino N, Nishimoto N. The blockade of IL-6 signaling in rational drug design. Curr Pharm Des 2008; 14(12): 1217-24.
185. Hamoudeh M, Kamleh MA, Diab R, Fessi H. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv Drug Deliv Rev 2008; 60(12): 1329-46.
186. Huwyler J, Drewe J, Krahenbuhl S. Tumor targeting using liposomal antineoplastic drugs. Int J Nanomedicine 2008; 3(1): 21-9.